These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1103 related articles for article (PubMed ID: 8531121)

  • 21. Platelet reactivity in vitro in relation to thromboxane in healthy pregnancy.
    Horn EH; Hardy E; Cooper J; Heptinstall S; Rubin PC
    Thromb Haemost; 1996 Feb; 75(2):346-51. PubMed ID: 8815588
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Agents combining thromboxane receptor antagonism with thromboxane synthase inhibition: [[[2-(1H-imidazol-1-yl)ethylidene]amino]oxy]alkanoic acids.
    Cozzi P; Giordani A; Menichincheri M; Pillan A; Pinciroli V; Rossi A; Tonani R; Volpi D; Tamburin M; Ferrario R
    J Med Chem; 1994 Oct; 37(21):3588-604. PubMed ID: 7932586
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of thromboxane A2 synthetase inhibition, singly and combined with thromboxane A2/prostaglandin endoperoxide receptor antagonism, on inositol phospholipid turnover and on 5-HT release by washed human platelets.
    de Chaffoy de Courcelles D; De Clerck F
    Eur J Pharmacol; 1990 Mar; 188(2-3):161-9. PubMed ID: 2318257
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Thromboxane A2-mediated shape change: independent of Gq-phospholipase C--Ca2+ pathway in rabbit platelets.
    Ohkubo S; Nakahata N; Ohizumi Y
    Br J Pharmacol; 1996 Mar; 117(6):1095-104. PubMed ID: 8882602
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacologic characterization of human and canine thromboxane A2/prostaglandin H2 receptors in platelets and blood vessels: evidence for different receptors.
    Mais DE; Saussy DL; Chaikhouni A; Kochel PJ; Knapp DR; Hamanaka N; Halushka PV
    J Pharmacol Exp Ther; 1985 May; 233(2):418-24. PubMed ID: 2987481
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Binding kinetics and antiplatelet activities of picotamide, a thromboxane A2 receptor antagonist.
    Modesti PA; Cecioni I; Colella A; Costoli A; Paniccia R; Neri Serneri GG
    Br J Pharmacol; 1994 May; 112(1):81-6. PubMed ID: 8032666
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Labeling of human platelet plasma membrane thromboxane A2/prostaglandin H2 receptors using SQB, a novel biotinylated receptor probe.
    Komiotis D; Wencel-Drake JD; Dieter JP; Lim CT; Le Breton GC
    Biochem Pharmacol; 1996 Sep; 52(5):763-70. PubMed ID: 8765474
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The cleavage of plasmenylethanolamine by phospholipase A2 appears to be mediated by the low affinity binding site of the TxA2/PGH2 receptor in U46619-stimulated human platelets.
    Turini ME; Holub BJ
    Biochim Biophys Acta; 1994 Jun; 1213(1):21-6. PubMed ID: 8011675
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phenol red is a thromboxane A2/prostaglandin H2 receptor antagonist in canine lingual arteries and human platelets.
    Greenberg SS; Johns A; Kleha J; Xie J; Wang Y; Bianchi J; Conley K
    J Pharmacol Exp Ther; 1994 Mar; 268(3):1352-61. PubMed ID: 8138950
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prostaglandin H2 in human platelet activation: coactivator and substitute for thromboxane A2.
    Hornberger WB; Patscheke H
    Prog Clin Biol Res; 1989; 301():315-9. PubMed ID: 2798452
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Thromboxane A2 synthase inhibition and thromboxane A2 receptor blockade by 2-[(4-cyanophenyl)amino]-3-chloro-1,4-naphthalenedione (NQ-Y15) in rat platelets.
    Chang TS; Kim HM; Lee KS; Khil LY; Mar WC; Ryu CK; Moon CK
    Biochem Pharmacol; 1997 Jul; 54(2):259-68. PubMed ID: 9271330
    [TBL] [Abstract][Full Text] [Related]  

  • 32. KRDS, a peptide derived from human lactotransferrin, inhibits thrombin-induced thromboxane synthesis by a cyclooxygenase-independent mechanism.
    Lévy-Toledano S; Grelac F; Caen JP; Maclouf J
    Thromb Haemost; 1995 May; 73(5):857-61. PubMed ID: 7482416
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Desensitization of platelet thromboxane A2/prostaglandin H2 receptors by the mimetic U46619.
    Liel N; Mais DE; Halushka PV
    J Pharmacol Exp Ther; 1988 Dec; 247(3):1133-8. PubMed ID: 2974487
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Defective signal transduction through the thromboxane A2 receptor in a patient with a mild bleeding disorder: deficiency of the inositol 1,4,5-triphosphate formation despite normal G-protein activation.
    Mitsui T; Yokoyama S; Shimizu Y; Katsuura M; Akiba K; Hayasaka K
    Thromb Haemost; 1997 May; 77(5):991-5. PubMed ID: 9184416
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Thromboxane (Tx) A2 receptor blockade and TxA2 synthase inhibition alone and in combination: comparison of anti-aggregatory efficacy in human platelets.
    Watts IS; Wharton KA; White BP; Lumley P
    Br J Pharmacol; 1991 Feb; 102(2):497-505. PubMed ID: 1826620
    [TBL] [Abstract][Full Text] [Related]  

  • 36. On the mechanism of the prolonged action in man of GR32191, a thromboxane receptor antagonist.
    Ritter JM; Doktor HS; Benjamin N; Barrow SE; Stewart-Long P
    Adv Prostaglandin Thromboxane Leukot Res; 1991; 21A():351-4. PubMed ID: 1825568
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Thromboxane A2/prostaglandin endoperoxide (TXA2/PG-END) receptor binding properties in human platelets of ridogrel, a combined TXA2 synthase inhibitor--TXA2/PG-END receptor antagonist.
    Heylen L; De Clerck F; Somers Y; Leysen JE
    Blood Coagul Fibrinolysis; 1991 Oct; 2(5):617-21. PubMed ID: 1838285
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Binding of an 125I-labeled thromboxane A2/prostaglandin H2 receptor antagonist to washed canine platelets.
    Mais DE; Kochel PJ; Saussy DL; Halushka PV
    Mol Pharmacol; 1985 Aug; 28(2):163-9. PubMed ID: 2991736
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vitro and in vivo pharmacological characterization of BM-613 [N-n-pentyl-N'-[2-(4'-methylphenylamino)-5-nitrobenzenesulfonyl]urea], a novel dual thromboxane synthase inhibitor and thromboxane receptor antagonist.
    Hanson J; Rolin S; Reynaud D; Qiao N; Kelley LP; Reid HM; Valentin F; Tippins J; Kinsella BT; Masereel B; Pace-Asciak C; Pirotte B; Dogné JM
    J Pharmacol Exp Ther; 2005 Apr; 313(1):293-301. PubMed ID: 15626721
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The protective effects of paclitaxel on platelet aggregation through the inhibition of thromboxane A2 synthase.
    Lee JJ; Yu JY; Lee JH; Zhang WY; Kim TJ; Myung CS; Yun YP
    Arch Pharm Res; 2010 Mar; 33(3):387-94. PubMed ID: 20361303
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 56.